Deziglipel

Deziglipel
Clinical data
Other names	MKP10241; MKP-10241
Routes of; administration	Oral
Drug class	GPR119 agonist; Antihyperglycemic agent
Identifiers
	IUPAC name 2-[(1S)-1-[1-(5-ethylpyrimidin-2-yl)piperidin-4-yl]ethoxy]-6-(2-fluoro-4-methylsulfonylphenyl)imidazo[2,1-b][1,3,4]thiadiazole;
CAS Number	2137977-29-6;
PubChem CID	131984581;
ChemSpider	138497087;
UNII	9N7Y669B85;
Chemical and physical data
Formula	C24H27FN6O3S2
Molar mass	530.64 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCC1=CN=C(N=C1)N2CCC(CC2)[C@H](C)OC3=NN4C=C(N=C4S3)C5=C(C=C(C=C5)S(=O)(=O)C)F;
	InChI InChI=1S/C24H27FN6O3S2/c1-4-16-12-26-22(27-13-16)30-9-7-17(8-10-30)15(2)34-24-29-31-14-21(28-23(31)35-24)19-6-5-18(11-20(19)25)36(3,32)33/h5-6,11-15,17H,4,7-10H2,1-3H3/t15-/m0/s1; Key:UUMBXZTUKTTYMG-HNNXBMFYSA-N;

Deziglipel (INNTooltip International Nonproprietary Name; developmental code name MKP10241) is a GPR119 agonist with antihyperglycemic actions which is under development for the treatment of obesity and type 2 diabetes.^[1]^[2] It is taken orally.^[1] The drug has been found to reduce glucose levels and HbA1c in rodents, including in models of diabetes.^[2] In addition, it markedly reduced feed intake and body weight in such rodents.^[2] The drug also reduced metabolic dysfunction–associated steatotic liver disease (MASLD) in a rodent model of the disease.^[2] Deziglipel is under development by Mankind Pharma.^[1] As of November 2025, it is in phase 2 clinical trials for both obesity and type 2 diabetes.^[1]

References

1 2 3 4 5 "MKP 10241". adisinsight.springer.com. Retrieved 28 October 2026.
1 2 3 4 Rai SK, Patil RI, Ali S, Kumar R, Khan MI, Panwar A, et al. (November 2025). "Discovery of MKP10241, a Novel Small Molecule Targeting the GPR119/Incretin Axis to Treat Metabolic Disorders". Journal of Medicinal Chemistry. 68 (22): 23781–23800. doi:10.1021/acs.jmedchem.5c00540. PMID 41054342.

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.